GSK199

GSK199 is an orally active, reversible, and selective PAD4 inhibitor with an IC50 of 200 nM in the absence of calcium. GSK199 can be used for the research of rheumatoid arthritis[1].

Product Specifications

CAS Number

[1549811-53-1]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Protein Arginine Deiminase

Type

Reference compound

Related Pathways

Epigenetics

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/gsk199.html

Purity

99.85

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(N1C[C@H](N)CCC1)C2=CC(OC)=C3C(N=C(C4=CC5=CC=CN=C5N4CC)N3C)=C2.[H]Cl

Molecular Formula

C24H29ClN6O2

Molecular Weight

468.98

Precautions

H315, H319, H320

References & Citations

[1]Lewis HD, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar;11 (3) :189-91. |[2]Pasquero S, et al. Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2. Antiviral Res. 2022 Apr;200:105278.|[3]Hallur G, et al. LC-ESI-MS/MS Determination of GSK-199, A Novel Reversible PAD4 Inhibitor in Mice Plasma and its Application to a Pharmacokinetic Study in Mice. Pharm Anal Chem. 2017, 3 (124) : 40-1.